Clinical Outcomes of Neovascular Glaucoma in Patients with Prior and Non-Prior Intravitreal Anti-VEGF Treatment: A Retrospective Cohort Study.

Clin Ophthalmol · 2026 · PMC13264403 · PMID 42294418

Europe PMC DOI

hedged sentence

0.1000

closest p · 2.0× alpha

0.1000

boldest claim

The sentences

borderline significantP=0.1so close (0.05 < p ≤ 0.1)

13 Conversely, Yazdani et al demonstrated a borderline significant reduction in medication use among eyes receiving adjunctive intravitreal Bevacizumab at Months 1 and 3 (P=0.1 and P=0.06 respectively), but not at Month 6 (P=0.18); nonetheless, in their comparison group, which received the same standard treatments, except for Bevacizumab, no reduction in medicatio

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.